Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Submission of Food and Drug Administration Adverse Event Reports and Other Safety Information Using the Electronic Submission Gateway and the Safety Reporting Portal, 3433-3437 [2013-00761]
Download as PDF
3433
Federal Register / Vol. 78, No. 11 / Wednesday, January 16, 2013 / Notices
ANNUAL BURDEN ESTIMATES—Continued
Annual
number of
respondents
Instrument
Collecting saliva to measure cotinine and cortisol, and measuring height
and weight ..................................................................................................
Estimated Total Annual Burden
Hours: 5,334
Copies of the proposed collection may
be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: OPRE Reports Clearance Officer.
All requests should be identified by the
title of the information collection. Email
address:
OPREinfocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email:
OIRA_SUBMISSION@OMB.EOP.GOV,
Attn: Desk Officer for the
Administration, for Children and
Families.
Steven M. Hanmer,
Reports Clearance, Officer.
[FR Doc. 2013–00592 Filed 1–15–13; 8:45 am]
BILLING CODE 4184–22–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0921]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Electronic
Submission of Food and Drug
Administration Adverse Event Reports
and Other Safety Information Using the
Electronic Submission Gateway and
the Safety Reporting Portal
mstockstill on DSK4VPTVN1PROD with
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
SUMMARY:
VerDate Mar<15>2010
17:01 Jan 15, 2013
Jkt 229001
Number of
responses per
respondent
2890
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(the PRA).
DATES: Fax written comments on the
collection of information by February
15, 2013.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0645. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400T, Rockville, MD 20850,
domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Electronic Submission of Food and
Drug Administration Adverse Event
Reports and Other Safety Information
Using the Electronic Submission
Gateway and the Safety Reporting
Portal—21 CFR 310.305, 314.80, 314.98,
314.540, 514.80, 600.80, 1271.350 and
Part 803 (OMB Control Number 0910–
0645)—Revision
The FDA Safety Reporting Portal (the
SRP) (formerly referred to as the
MedWatchPlus Portal and Rational
Questionnaire) and the Electronic
Submission Gateway (ESG) are the
Agency’s electronic systems for
collecting, submitting, and processing
adverse event reports and other safety
information for FDA-regulated products.
To ensure the safety and identify any
risks, harms, or other dangers to health
for all FDA-regulated human and animal
products, the Agency needs to be
informed whenever an adverse event,
product quality problem, or product use
error occurs. This risk identification
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
1
Average burden
hours per
response
Total annual
burden hours
0.3
867
process is the first necessary step that
allows the Agency to gather the
information necessary to be able to
evaluate the risk associated with the
product and take whatever action is
necessary to mitigate or eliminate the
public’s exposure to the risk.
Some adverse event reports are
required to be submitted to FDA
(mandatory reporting) and some adverse
event reports are submitted voluntarily
(voluntary reporting). Requirements
regarding mandatory reporting of
adverse events or product problems
have been codified in 21 CFR parts 310,
314, 514, 600, 803 and 1271, specifically
§§ 310.305, 314.80, 314.98, 314.540,
514.80, 600.80, 803.30, 803.40, 803.50,
803.53, 803.56 and 1271.350(a) (21 CFR
310.305, 314.80, 314.98, 314.540,
514.80, 600.80, 803.30, 803.40, 803.50,
803.53, 803.56 and 1271.350(a)). Many
of the adverse event reports submitted
to FDA are currently filed in paper
format using FDA Forms FDA 3500,
3500A, 1932, and 1932a, approved
under OMB control numbers 0910–0284
and 0910–0291. This notice solicits
comments on adverse event reports filed
electronically via the SRP and the ESG,
approved under OMB control number
0910–0645.
I. The FDA Safety Reporting Portal
Rational Questionnaires
FDA currently has OMB approval to
receive three types of adverse event
reports electronically via the SRP using
rational questionnaires. FDA sought
comments on the extension of OMB
approval for the existing three rational
questionnaires, as well as comments on
a proposed fourth rational questionnaire
that will be used for a new safety
reporting program being launched by
the Center for Tobacco Products (CTP).
A. Reportable Food Registry Reports
The Food and Drug Administration
Amendments Act of 2007 (Pub. L. 110–
85) (FDAAA) amended the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) by creating a new section
417 (21 U.S.C. 350f), Reportable Food
Registry (RFR or the Registry). Section
417 of the FD&C Act defines ‘‘reportable
food’’ as an ‘‘article of food (other than
infant formula or dietary supplements)
for which there is a reasonable
E:\FR\FM\16JAN1.SGM
16JAN1
3434
Federal Register / Vol. 78, No. 11 / Wednesday, January 16, 2013 / Notices
probability that the use of, or exposure
to, such article of food will cause
serious adverse health consequences or
death to humans or animals.’’ (See
section 417(a)(2) of the FD&C Act). The
Secretary of Health and Human Services
(the Secretary) has delegated to the
Commissioner of FDA the responsibility
for administering the FD&C Act,
including section 417. To further the
development of the RFR, section 417 of
the FD&C Act required FDA to establish
an electronic portal by which instances
of reportable food (‘‘RFR reports’’) must
be submitted to FDA by responsible
parties and may be submitted by public
health officials. A ‘‘responsible party’’ is
the person who submits the registration
under section 415(a) of the FD&C Act
(21 U.S.C. 350d) for a food facility that
is required to register under section
415(a), at which such article of food is
manufactured, processed, packed, or
held. The RFR electronic portal was
established in 2009 as part of the
MedWatchPlus Portal, now the SRP, and
approved under OMB control number
0910–0645.
The Congressionally identified
purpose of the RFR is to provide ‘‘a
reliable mechanism to track patterns of
adulteration in food [which] would
support efforts by the Food and Drug
Administration to target limited
inspection resources to protect the
public health’’ (121 Stat. 965). The RFR
reports are designed to enable FDA to
quickly identify, track, and remove from
commerce an article of food (other than
infant formula and dietary supplements)
for which there is a reasonable
probability that the use of, or exposure
to, such article of food will cause
serious adverse health consequences or
death to humans or animals. FDA uses
the information collected to help ensure
that such products are quickly and
efficiently removed from the market to
prevent foodborne illnesses.
On January 4, 2011, the President
signed into law the FDA Food Safety
Modernization Act (Pub. L. 111–353)
(the legislation or FSMA). Section 211
of the legislation amended section 417
of the FD&C Act to require FDA to
collect additional information in the
Agency’s RFR reports: (1) A description
of the article of food; (2) affected
product identification codes, such as
universal product code (UPC), stock
keeping unit, or lot or batch numbers
sufficient for the consumer to identify
the article of food; (3) contact
information for the responsible party;
and (4) any other information the
Secretary determines is necessary to
enable a consumer to accurately identify
whether such consumer is in possession
of the reportable food.
Section 211 of FSMA also amended
section 417 of the FD&C Act to require
FDA to generate one-page notices from
RFR reports to post on www.fda.gov for
grocery stores to display to consumers
when a reportable food has been sold.
The amendment made by section 211 of
FSMA took effect June 4, 2012, 18
months after the date of enactment. To
comply with this statutory deadline,
FDA initially obtained OMB approval of
the additional collection of information
requirements under the emergency
processing provisions of the PRA under
OMB control number 0910–0709. The
new data improves the RFR’s
effectiveness in carrying out its purpose
of tracking patterns of adulteration in
food and supporting FDA’s efforts to
target limited inspection resources to
protect the public health.
Table 1 of this document, entitled
‘‘New Data Elements for RFR Reports,’’
presents the new data elements added
by FDA to RFR Reports on June 4, 2012.
TABLE 1—NEW DATA ELEMENTS FOR RFR REPORTS
Mandatory or optional input
Reason this food is reportable (agent) ....................
What did your investigation identify as the root
cause of the problem (if you were required to
conduct
an
investigation
under
section
417(d)(1)(B) of the FD&C Act)?
How did you determine which products/lots/
batches were affected?
To the best of your knowledge, has all of the reportable food been removed from commerce?
What corrective actions have been taken to prevent future occurrences?
Product commodity type ..........................................
Manufacturing/production date(s) ............................
Use-by dates, if any, or approximate shelf life ........
Was product treated to reduce microorganisms?
Microbial reduction treatment details .......................
Mandatory ..............................................
Mandatory ..............................................
Section 417(e)(4) of the FD&C Act.
Section 417(e)(5) of the FD&C Act.
Mandatory ..............................................
Section 417(e)(4) and (5) of the FD&C Act.
Mandatory ..............................................
Section 417(e)(6) of the FD&C Act.
Mandatory
Mandatory
Mandatory
Mandatory
Mandatory
Is a bacterial isolate available for collection?
Mandatory (but conditional) ...................
Animal species intended for ....................................
Life stage of animal intended for .............................
Have you notified all immediate previous sources
of this reportable food?
Have you notified all immediate subsequent recipients of this reportable food?
mstockstill on DSK4VPTVN1PROD with
Field text
Mandatory ..............................................
Mandatory ..............................................
Optional.
In this request for extension of OMB
approval, FDA is combining the burden
hours associated with OMB control
number 0910–0709 with the burden
VerDate Mar<15>2010
17:01 Jan 15, 2013
Jkt 229001
Optional.
..............................................
..............................................
..............................................
(but conditional) ...................
(but conditional) ...................
Mandatory ..............................................
hours approved under this OMB control
number (0910–0645).
PO 00000
Authority if mandatory
Section 417(e)(3) of the FD&C Act.
Section 417(e)(3) and (4) of the FD&C Act.
Section 417(e)(7) of the FD&C Act.
Section 417(e)(3) and (4) of the FD&C Act.
Section 417(e)(3) and (4) of the FD&C Act (Conditional for microbial hazards only and only
after ‘‘yes’’ answer to ‘‘Was product treated to
reduce microorganisms?’’).
Section 417(e)(4) of the FD&C Act (Conditional
for microbial hazards only.)
Section 417(e)(3) and (4) of the FD&C Act.
Section 417(e)(3) and (4) of the FD&C Act.
Section 417(e)(6) of the FD&C Act.
B. Reports Concerning Experience With
Approved New Animal Drugs
Section 512(l) of the FD&C Act (21
U.S.C. 360b(l)) and § 514.80(b)) require
applicants of approved new animal drug
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\16JAN1.SGM
16JAN1
Federal Register / Vol. 78, No. 11 / Wednesday, January 16, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with
applications (NADAs) and approved
abbreviated new animal drug
applications (ANADAs) to report
adverse drug experiences and product/
manufacturing defects.
This continuous monitoring of
approved NADAs and ANADAs affords
the primary means by which FDA
obtains information regarding potential
problems with the safety and efficacy of
marketed approved new animal drugs as
well as potential product/manufacturing
problems. Postapproval marketing
surveillance is important because data
previously submitted to FDA may no
longer be adequate, as animal drug
effects can change over time and less
apparent effects may take years to
manifest.
If an applicant must report adverse
drug experiences and product/
manufacturing defects and chooses to
do so using the Agency’s paper forms,
the applicant is required to use Form
FDA 1932, ‘‘Veterinary Adverse Drug
Reaction, Lack of Effectiveness, Product
Defect Report.’’ Periodic drug
experience reports and special drug
experience reports must be
accompanied by a completed Form FDA
2301, ‘‘Transmittal of Periodic Reports
and Promotional Material for New
Animal Drugs’’ (see § 514.80(d)). Form
FDA 1932a, ‘‘Veterinary Adverse Drug
Reaction, Lack of Effectiveness or
Product Defect Report’’ allows for
voluntary reporting of adverse drug
experiences or product/manufacturing
defects. Collection of information using
existing paper forms FDA 2301, 1932,
and 1932a is approved under OMB
control number 0910–0284.
Alternatively, an applicant may choose
to report adverse drug experiences and
product/manufacturing defects
electronically. Collection of this
information electronically was approved
in 2010 under OMB control number
0910–0645. The electronic submission
data elements to report adverse drug
experiences and product/manufacturing
defects electronically remain unchanged
in this request for extension of OMB
approval.
C. Pet Food Early Warning System
Section 1002(b) of FDAAA directed
the Secretary to establish an early
warning and surveillance system to
identify adulteration of the pet food
supply and outbreaks of illness
associated with pet food. As part of the
effort to fulfill that directive, the
Secretary tasked FDA with developing
the instrument that would allow
consumers to report voluntarily adverse
events associated with pet food.
FDA developed the Pet Food Early
Warning System rational questionnaire
VerDate Mar<15>2010
17:01 Jan 15, 2013
Jkt 229001
as a user-friendly data collection tool, to
make it easy for the public to report a
safety problem with pet food. The Pet
Food Early Warning System is designed
to identify adulteration of the pet food
supply and outbreaks of illness
associated with pet food to enable FDA
to quickly identify, track and remove
from commerce such articles of food.
FDA uses the information collected to
help ensure that such products are
quickly and efficiently removed from
the market to prevent foodborne
illnesses. In 2010, OMB approved the
Pet Food Early Warning System
component of the SRP under OMB
control number 0910–0645, and FDA
launched the rational questionnaire by
which consumers may electronically
report adverse events associated with
pet food. The electronic submission data
elements to report adverse events
associated with pet food remain
unchanged in this request for extension
of OMB approval.
D. Voluntary Tobacco Product Adverse
Event and Product Problem Reports
As noted, this notice seeks comments
on a proposed fourth rational
questionnaire that will be used for a
new safety reporting program being
launched by the CTP to collect
voluntary tobacco product adverse event
and product problem reports.
FDA has broad legal authority under
the FD&C Act to protect the public
health. CTP’s mission is to protect
Americans from tobacco-related death
and disease by regulating the
manufacture, distribution, and
marketing of tobacco products and by
educating the public, especially young
people, about tobacco products and the
dangers their use poses to themselves
and others. The Family Smoking
Prevention and Tobacco Control Act of
2009 (Pub. L. 111–31) (Tobacco Control
Act) amended the FD&C Act by creating
a new section 909 (21 U.S.C. 387i,
Records and Reports on Tobacco
Products). Section 909(a) of the FD&C
Act (21 U.S.C. 387i(a)) authorizes FDA
to establish regulations with respect to
mandatory adverse event reports
associated with the use of a tobacco
product. At this time, FDA is proposing
to collect voluntary adverse event
reports associated with the use of
tobacco products from interested parties
such as health care providers,
researchers, consumers and other users
of tobacco products. Information
collected in voluntary adverse event
reports will contribute to CTP’s ability
to be informed of, and assess the real
consequences of, tobacco product use.
The need for this collection of
information derives from our objective
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
3435
to obtain current, timely, and policyrelevant information to carry out our
statutory functions. The FDA
Commissioner is authorized to
undertake this collection as specified in
section 1003(d)(2) of the FD&C Act (21
U.S.C. 393(d)(2)).
CTP currently receives adverse event
and product problem reports primarily
via paper MedWatch forms, approved
under OMB control number 0910–0291.
MedWatch forms, although recently
updated with field labels and
descriptions to better clarify for
reporters the range of reportable
products, including tobacco products,
do not specifically include questions
relevant for the analysis of adverse
events or product problems related to
tobacco products. The proposed
voluntary tobacco product adverse event
and product problem rational
questionnaire will include these specific
questions. The questionnaire evolved
with input from a National Institutes of
Health team of human-factors experts,
from other regulatory Agencies, and
with extensive input from consumer
advocacy groups and the general public.
FDA is also working with the FDA
Internet team to follow the Department
of Health and Human Services Internet
guidelines for Web design. FDA has and
will continue to reach out to
professional organizations and
community interest groups to collect
feedback during the user acceptance
testing. The rational questionnaire will
provide the user with detailed
navigation instructions to include dropdown menus, lists of values, controlled
vocabularies, and mouse over help
where possible. In addition, CTP will
issue guidance for the rational
questionnaire. Finally, we note that
users who are unable to submit reports
using the electronic system will still be
able to provide their information by
paper form (by mail or FAX) or
telephone.
The proposed voluntary tobacco
product adverse event and product
problem rational questionnaire requests
the following information:
Introductory Information About the
Submission
• Whether the submission is a new
report, or a followup or amendment to
a previously transmitted report.
Information About the Sender and the
Affected Person
• Unless the sender wishes to remain
anonymous, the name of and contact
information for the person sending the
report; and
• Unless the affected person wishes
to remain anonymous, the name, contact
E:\FR\FM\16JAN1.SGM
16JAN1
3436
Federal Register / Vol. 78, No. 11 / Wednesday, January 16, 2013 / Notices
information, and demographic
information for the person who
experienced the adverse event.
Details of Any Attachments
• The type of attachment and a
description of it.
Tobacco Product Details
• Information about the product that
is the subject of the report, such as the
brand name, product name, UPC, and a
description of the tobacco product or
component;
• Information about the product or
component purchase date and location;
and
• Information about the manufacturer
of the product or component.
Problem Summary
• Information about the product
problem or adverse event, such as the
date and duration of the problem or
adverse event, a description of the use
of the product, a description of the
product problem or adverse event, and
a description of the main symptoms or
health problems.
• Information about the medical
treatment received by the affected
person, such as whether the person was
taken to an emergency facility, a
description of any medical testing or
treatment performed, and the results of
any tests;
• Information about any similar
product problems or adverse events
previously had by the affected person;
and
• In the event of death, the date of
death and the reported cause of death.
Other Products Used
• Information about the affected
person’s use of other tobacco products,
alcohol, prescription medications, overthe-counter medications, vitamins, or
dietary supplements.
The rational questionnaire will
capture tobacco-specific adverse event
and product problem information from
voluntary reporting entities such as
health care providers, researchers,
consumers, and other users of tobacco
products. To carry out its
responsibilities, FDA needs to be
informed when an adverse event,
product problem, or error with use is
suspected or identified. When FDA
receives tobacco-specific adverse event
and product problem information, it
will use the information to assess and
evaluate the risk associated with the
product, and then FDA will take
whatever action is necessary to reduce,
mitigate, or eliminate the public’s
exposure to the risk through regulatory
and public health interventions.
In the Federal Register of September
14, 2012 (77 FR 56847), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
II. Information Collection Burden
Estimate
Description of respondents: The
respondents to this collection of
information include all persons
submitting mandatory or voluntary
adverse event reports electronically to
FDA via the ESG or the SRP.
FDA estimates the burden of this
collection of information as follows:
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of
respondents
FDA Form No.
Voluntary Adverse Event Report via the
SRP (Other than RFR Reports). ..........
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
3800
1,513
1
1,513
0.6
(36 minutes)
908
Mandatory Adverse Event Report via the
SRP (Other than RFR Reports). ..........
Mandatory Adverse Event Report via the
ESG
(Gateway-to-Gateway
transmission). ...............................................
3800
636
1
636
1
636
3800
1,491,228
1
1,491,228
0.6
(36 minutes)
894,737
Mandatory and Voluntary RFR Reports
via the SRP. .........................................
3800
1,413
1
1,413
0.6
(36 minutes)
848
Total ..................................................
........................
........................
........................
........................
........................
897,129
mstockstill on DSK4VPTVN1PROD with
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The Agency’s estimate of the number
of respondents and the total annual
responses in table 2, Estimated Annual
Reporting Burden, is based primarily on
mandatory and voluntary adverse event
reports electronically submitted to the
Agency. The estimated total annual
responses are based on initial reports.
Followup reports, if any, are not
counted as new reports. Based on its
experience with adverse event
reporting, FDA estimates that it will
take a respondent 0.6 hour to submit a
voluntary adverse event report via the
SRP, 1 hour to submit a mandatory
adverse event report via the SRP, and
0.6 hour to submit a mandatory adverse
VerDate Mar<15>2010
17:01 Jan 15, 2013
Jkt 229001
event report via the ESG (gateway-togateway transmission). Both mandatory
and voluntary RFR reports must be
submitted via the SRP. FDA estimates
that it will take a respondent 0.6 hour
to submit a RFR report, whether the
submission is mandatory or voluntary.
Voluntary adverse event reports
submitted via the SRP (other than RFR
Reports) include reports associated with
pet food (the Pet Food Early Warning
System) and the new tobacco product
adverse event and product problem
reports. The Center for Veterinary
Medicine (CVM) received 845 pet food
adverse event reports in 2010; 1,293
reports in 2011; and 471 reports in the
first 4 months of 2012, and estimates
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
that for the full 12 months of 2012 it
will receive 1,413 reports. Based on this
experience, CVM estimates that it will
receive, on average, 1,413 pet food
reports annually over the next 3 years.
CTP estimates that it will receive
approximately 100 voluntary tobacco
product adverse event and product
problem reports annually, after
implementation of electronic reporting.
CTP received 27 reports in 2010, 30
reports in 2011, and 22 reports in the
first half of 2012, and estimates that for
the full 12 months of 2012 it will
receive over 40 reports. Based on this
experience and an expectation that
reporting will increase once electronic
E:\FR\FM\16JAN1.SGM
16JAN1
mstockstill on DSK4VPTVN1PROD with
Federal Register / Vol. 78, No. 11 / Wednesday, January 16, 2013 / Notices
reporting is launched, CTP estimates
that it will receive, on average, 100
voluntary adverse event and product
problem reports annually over the next
3 years. Thus, FDA estimates that over
the next 3 years it will receive annually
1,513 voluntary adverse event reports
submitted via the SRP, with a burden of
907.8 hours, rounded to 908 hours, as
reported in table 2, row 1 (1,413 + 100
= 1,513).
Mandatory adverse event reports
submitted via the SRP (other than RFR
Reports) include reports of adverse
animal drug experiences and product/
manufacturing defects associated with
approved NADAs and ANADAs. CVM
received 144 such adverse event reports
in 2010, 537 reports in 2011, and 212
reports in the first four months of 2012,
and estimates that for the full 12 months
of 2012 it will receive 636 reports.
Based on this experience, CVM
estimates that it will receive, on average,
636 reports of adverse drug experiences
and product/manufacturing defects
associated with approved NADAs and
ANADAs annually over the next 3 years.
Thus, FDA estimates that over the next
3 years it will receive annually 636
mandatory adverse event reports
submitted via the SRP, with a burden of
636 hours, as reported in table 2, row 2.
Adverse event reports submitted via
the ESG include reports of adverse
experiences related to drugs, biological
products, and medical devices, as well
as, adverse animal drug experiences and
product/manufacturing defects
associated with approved NADAs and
ANADAs. FDA received 586,229 such
adverse event reports in 2010; 850,161
reports in 2011; and 497,076 reports in
the first 4 months of 2012; and estimates
that for the full 12 months of 2012 it
will receive 1,491,228 reports. Based on
this experience, FDA estimates that it
will receive, on average, 1,491,228
adverse event reports submitted via the
ESG, with a burden of 894,736.8 hours,
rounded to 894,737 hours, as reported
in table 2, row 3.
FDA estimates that over the next 3
years it will receive annually 1,413
mandatory and voluntary RFR Reports
submitted via the SRP, as reported in
table 2, row 4. The Center for Food
Safety and Applied Nutrition (CFSAN)
received 845 such adverse event reports
in 2010; 1,293 reports in 2011; and 471
reports in the first four months of 2012;
and estimates that for the full 12 months
of 2012 it will receive 1,413 reports.
Based on this experience, CFSAN
estimates that it will receive, on average,
1,413 mandatory and voluntary RFR
Reports submitted via the SRP annually
over the next 3 years, with a burden of
VerDate Mar<15>2010
17:01 Jan 15, 2013
Jkt 229001
847.8 hours, rounded to 848 hours, as
reported in table 2, row 4.
The burden hours required to
complete paper FDA reporting forms
(Forms FDA 3500, 3500A, 1932, and
1932a) are reported under OMB control
numbers 0910–0284 and 0910–0291.
While FDA does not charge for the
use of the ESG, FDA requires
respondents to obtain a public key
infrastructure certificate in order to set
up the account. This can be obtained inhouse or outsourced by purchasing a
public key certificate that is valid for 1
year to 3 years. The certificate typically
costs from $20 to $30.
Dated: January 10, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–00761 Filed 1–15–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Optical Microscope Software for Breast
Cancer Diagnosis
Description of Technology: The
instant invention discloses a software to
analyze optical microscopic images of
human breast tissue sections for
diagnosing cancer by using the
differences in spatial positioning of
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
3437
certain genes. The software uses the
inherent hierarchy in the data and stores
all the analysis and manual interaction
information in a highly structured XML
file. It is a user-friendly software to
discriminate normal and cancerous
human breast tissue section images that
can be used for large experiments.
Additionally the software uses a cluster
of computers in the background to
reduce the analysis time for large image
datasets. Furthermore, the software of
instant invention provides a set of tools
for performing diagnostic or prognostic
assays on new unseen datasets.
Potential Commercial Applications:
• The software could be an essential
part of an integrated diagnostic or
prognostic assay for breast cancer
detection.
• The software could be a key tool for
biomedical research to test new markers
and their applicability for diagnostic
purposes.
• The use of the software could
provide important information for
understanding the underlying causes of
gene repositioning.
Competitive Advantages:
• The software of instant invention
can be used to analyze relatively large
datasets.
• To reduce the processing time by at
least 10 fold.
• The software can be used in a broad
range of quantitative image analysis
applications.
Development Stage:
• Prototype
• Clinical
• In vitro data available (human)
Inventors: Kaustav Nandy (SAICFrederick, Inc), Stephen J. Lockett
(SAIC-Frederick, Inc), Prabhakar R.
Gudla (SAIC-Frederick, Inc), William
Cukierski (NCI), Renee Qian (NCI),
Karen J. Meaburn (NCI), Tom Misteli
(NCI).
Publications:
1. Gudla PR, et al. A high-throughput
system for segmenting nuclei using
multiscale techniques. Cytometry A.
2008 May;73(5):451–66. [PMID
18338778]
2. Nandy K, et al. Automatic nuclei
segmentation and spatial FISH analysis
for cancer detection. Conf Proc IEEE Eng
Med Biol Soc. 2009;2009:6718–21.
[PMID 19963931].
3. Meaburn KJ, et al. Disease-specific
gene repositioning in breast cancer. J
Cell Biol. 2009 Dec 14;187(6):801–12.
[PMID 19995938].
4. Cukierski WJ, et al. Ranked
retrieval of segmented nuclei for
objective assessment of cancer gene
repositioning. BMC Bioinformatics.
2012 Sep 12;13:232. [PMID: 22971117].
5. Nandy K, et al. Supervised learning
framework for screening nuclei in tissue
E:\FR\FM\16JAN1.SGM
16JAN1
Agencies
[Federal Register Volume 78, Number 11 (Wednesday, January 16, 2013)]
[Notices]
[Pages 3433-3437]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00761]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0921]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Electronic Submission
of Food and Drug Administration Adverse Event Reports and Other Safety
Information Using the Electronic Submission Gateway and the Safety
Reporting Portal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995 (the PRA).
DATES: Fax written comments on the collection of information by
February 15, 2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0645.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400T,
Rockville, MD 20850, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Electronic Submission of Food and Drug Administration Adverse Event
Reports and Other Safety Information Using the Electronic Submission
Gateway and the Safety Reporting Portal--21 CFR 310.305, 314.80,
314.98, 314.540, 514.80, 600.80, 1271.350 and Part 803 (OMB Control
Number 0910-0645)--Revision
The FDA Safety Reporting Portal (the SRP) (formerly referred to as
the MedWatch\Plus\ Portal and Rational Questionnaire) and the
Electronic Submission Gateway (ESG) are the Agency's electronic systems
for collecting, submitting, and processing adverse event reports and
other safety information for FDA-regulated products. To ensure the
safety and identify any risks, harms, or other dangers to health for
all FDA-regulated human and animal products, the Agency needs to be
informed whenever an adverse event, product quality problem, or product
use error occurs. This risk identification process is the first
necessary step that allows the Agency to gather the information
necessary to be able to evaluate the risk associated with the product
and take whatever action is necessary to mitigate or eliminate the
public's exposure to the risk.
Some adverse event reports are required to be submitted to FDA
(mandatory reporting) and some adverse event reports are submitted
voluntarily (voluntary reporting). Requirements regarding mandatory
reporting of adverse events or product problems have been codified in
21 CFR parts 310, 314, 514, 600, 803 and 1271, specifically Sec. Sec.
310.305, 314.80, 314.98, 314.540, 514.80, 600.80, 803.30, 803.40,
803.50, 803.53, 803.56 and 1271.350(a) (21 CFR 310.305, 314.80, 314.98,
314.540, 514.80, 600.80, 803.30, 803.40, 803.50, 803.53, 803.56 and
1271.350(a)). Many of the adverse event reports submitted to FDA are
currently filed in paper format using FDA Forms FDA 3500, 3500A, 1932,
and 1932a, approved under OMB control numbers 0910-0284 and 0910-0291.
This notice solicits comments on adverse event reports filed
electronically via the SRP and the ESG, approved under OMB control
number 0910-0645.
I. The FDA Safety Reporting Portal Rational Questionnaires
FDA currently has OMB approval to receive three types of adverse
event reports electronically via the SRP using rational questionnaires.
FDA sought comments on the extension of OMB approval for the existing
three rational questionnaires, as well as comments on a proposed fourth
rational questionnaire that will be used for a new safety reporting
program being launched by the Center for Tobacco Products (CTP).
A. Reportable Food Registry Reports
The Food and Drug Administration Amendments Act of 2007 (Pub. L.
110-85) (FDAAA) amended the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) by creating a new section 417 (21 U.S.C. 350f), Reportable
Food Registry (RFR or the Registry). Section 417 of the FD&C Act
defines ``reportable food'' as an ``article of food (other than infant
formula or dietary supplements) for which there is a reasonable
[[Page 3434]]
probability that the use of, or exposure to, such article of food will
cause serious adverse health consequences or death to humans or
animals.'' (See section 417(a)(2) of the FD&C Act). The Secretary of
Health and Human Services (the Secretary) has delegated to the
Commissioner of FDA the responsibility for administering the FD&C Act,
including section 417. To further the development of the RFR, section
417 of the FD&C Act required FDA to establish an electronic portal by
which instances of reportable food (``RFR reports'') must be submitted
to FDA by responsible parties and may be submitted by public health
officials. A ``responsible party'' is the person who submits the
registration under section 415(a) of the FD&C Act (21 U.S.C. 350d) for
a food facility that is required to register under section 415(a), at
which such article of food is manufactured, processed, packed, or held.
The RFR electronic portal was established in 2009 as part of the
MedWatch\Plus\ Portal, now the SRP, and approved under OMB control
number 0910-0645.
The Congressionally identified purpose of the RFR is to provide ``a
reliable mechanism to track patterns of adulteration in food [which]
would support efforts by the Food and Drug Administration to target
limited inspection resources to protect the public health'' (121 Stat.
965). The RFR reports are designed to enable FDA to quickly identify,
track, and remove from commerce an article of food (other than infant
formula and dietary supplements) for which there is a reasonable
probability that the use of, or exposure to, such article of food will
cause serious adverse health consequences or death to humans or
animals. FDA uses the information collected to help ensure that such
products are quickly and efficiently removed from the market to prevent
foodborne illnesses.
On January 4, 2011, the President signed into law the FDA Food
Safety Modernization Act (Pub. L. 111-353) (the legislation or FSMA).
Section 211 of the legislation amended section 417 of the FD&C Act to
require FDA to collect additional information in the Agency's RFR
reports: (1) A description of the article of food; (2) affected product
identification codes, such as universal product code (UPC), stock
keeping unit, or lot or batch numbers sufficient for the consumer to
identify the article of food; (3) contact information for the
responsible party; and (4) any other information the Secretary
determines is necessary to enable a consumer to accurately identify
whether such consumer is in possession of the reportable food.
Section 211 of FSMA also amended section 417 of the FD&C Act to
require FDA to generate one-page notices from RFR reports to post on
www.fda.gov for grocery stores to display to consumers when a
reportable food has been sold. The amendment made by section 211 of
FSMA took effect June 4, 2012, 18 months after the date of enactment.
To comply with this statutory deadline, FDA initially obtained OMB
approval of the additional collection of information requirements under
the emergency processing provisions of the PRA under OMB control number
0910-0709. The new data improves the RFR's effectiveness in carrying
out its purpose of tracking patterns of adulteration in food and
supporting FDA's efforts to target limited inspection resources to
protect the public health.
Table 1 of this document, entitled ``New Data Elements for RFR
Reports,'' presents the new data elements added by FDA to RFR Reports
on June 4, 2012.
Table 1--New Data Elements for RFR Reports
------------------------------------------------------------------------
Mandatory or Authority if
Field text optional input mandatory
------------------------------------------------------------------------
Reason this food is reportable Mandatory........ Section 417(e)(4) of
(agent). the FD&C Act.
What did your investigation Mandatory........ Section 417(e)(5) of
identify as the root cause of the FD&C Act.
the problem (if you were
required to conduct an
investigation under section
417(d)(1)(B) of the FD&C
Act)?
How did you determine which Mandatory........ Section 417(e)(4) and
products/lots/batches were (5) of the FD&C Act.
affected?
To the best of your knowledge, Mandatory........ Section 417(e)(6) of
has all of the reportable the FD&C Act.
food been removed from
commerce?
What corrective actions have Optional.........
been taken to prevent future
occurrences?
Product commodity type........ Mandatory........ Section 417(e)(3) of
the FD&C Act.
Manufacturing/production Mandatory........ Section 417(e)(3) and
date(s). (4) of the FD&C Act.
Use-by dates, if any, or Mandatory........ Section 417(e)(7) of
approximate shelf life. the FD&C Act.
Was product treated to reduce Mandatory (but Section 417(e)(3) and
microorganisms? conditional). (4) of the FD&C Act.
Microbial reduction treatment Mandatory (but Section 417(e)(3) and
details. conditional). (4) of the FD&C Act
(Conditional for
microbial hazards
only and only after
``yes'' answer to
``Was product
treated to reduce
microorganisms?'').
Is a bacterial isolate Mandatory (but Section 417(e)(4) of
available for collection? conditional). the FD&C Act
(Conditional for
microbial hazards
only.)
Animal species intended for... Mandatory........ Section 417(e)(3) and
(4) of the FD&C Act.
Life stage of animal intended Mandatory........ Section 417(e)(3) and
for. (4) of the FD&C Act.
Have you notified all Optional.........
immediate previous sources of
this reportable food?
Have you notified all Mandatory........ Section 417(e)(6) of
immediate subsequent the FD&C Act.
recipients of this reportable
food?
------------------------------------------------------------------------
In this request for extension of OMB approval, FDA is combining the
burden hours associated with OMB control number 0910-0709 with the
burden hours approved under this OMB control number (0910-0645).
B. Reports Concerning Experience With Approved New Animal Drugs
Section 512(l) of the FD&C Act (21 U.S.C. 360b(l)) and Sec.
514.80(b)) require applicants of approved new animal drug
[[Page 3435]]
applications (NADAs) and approved abbreviated new animal drug
applications (ANADAs) to report adverse drug experiences and product/
manufacturing defects.
This continuous monitoring of approved NADAs and ANADAs affords the
primary means by which FDA obtains information regarding potential
problems with the safety and efficacy of marketed approved new animal
drugs as well as potential product/manufacturing problems. Postapproval
marketing surveillance is important because data previously submitted
to FDA may no longer be adequate, as animal drug effects can change
over time and less apparent effects may take years to manifest.
If an applicant must report adverse drug experiences and product/
manufacturing defects and chooses to do so using the Agency's paper
forms, the applicant is required to use Form FDA 1932, ``Veterinary
Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.''
Periodic drug experience reports and special drug experience reports
must be accompanied by a completed Form FDA 2301, ``Transmittal of
Periodic Reports and Promotional Material for New Animal Drugs'' (see
Sec. 514.80(d)). Form FDA 1932a, ``Veterinary Adverse Drug Reaction,
Lack of Effectiveness or Product Defect Report'' allows for voluntary
reporting of adverse drug experiences or product/manufacturing defects.
Collection of information using existing paper forms FDA 2301, 1932,
and 1932a is approved under OMB control number 0910-0284.
Alternatively, an applicant may choose to report adverse drug
experiences and product/manufacturing defects electronically.
Collection of this information electronically was approved in 2010
under OMB control number 0910-0645. The electronic submission data
elements to report adverse drug experiences and product/manufacturing
defects electronically remain unchanged in this request for extension
of OMB approval.
C. Pet Food Early Warning System
Section 1002(b) of FDAAA directed the Secretary to establish an
early warning and surveillance system to identify adulteration of the
pet food supply and outbreaks of illness associated with pet food. As
part of the effort to fulfill that directive, the Secretary tasked FDA
with developing the instrument that would allow consumers to report
voluntarily adverse events associated with pet food.
FDA developed the Pet Food Early Warning System rational
questionnaire as a user-friendly data collection tool, to make it easy
for the public to report a safety problem with pet food. The Pet Food
Early Warning System is designed to identify adulteration of the pet
food supply and outbreaks of illness associated with pet food to enable
FDA to quickly identify, track and remove from commerce such articles
of food. FDA uses the information collected to help ensure that such
products are quickly and efficiently removed from the market to prevent
foodborne illnesses. In 2010, OMB approved the Pet Food Early Warning
System component of the SRP under OMB control number 0910-0645, and FDA
launched the rational questionnaire by which consumers may
electronically report adverse events associated with pet food. The
electronic submission data elements to report adverse events associated
with pet food remain unchanged in this request for extension of OMB
approval.
D. Voluntary Tobacco Product Adverse Event and Product Problem Reports
As noted, this notice seeks comments on a proposed fourth rational
questionnaire that will be used for a new safety reporting program
being launched by the CTP to collect voluntary tobacco product adverse
event and product problem reports.
FDA has broad legal authority under the FD&C Act to protect the
public health. CTP's mission is to protect Americans from tobacco-
related death and disease by regulating the manufacture, distribution,
and marketing of tobacco products and by educating the public,
especially young people, about tobacco products and the dangers their
use poses to themselves and others. The Family Smoking Prevention and
Tobacco Control Act of 2009 (Pub. L. 111-31) (Tobacco Control Act)
amended the FD&C Act by creating a new section 909 (21 U.S.C. 387i,
Records and Reports on Tobacco Products). Section 909(a) of the FD&C
Act (21 U.S.C. 387i(a)) authorizes FDA to establish regulations with
respect to mandatory adverse event reports associated with the use of a
tobacco product. At this time, FDA is proposing to collect voluntary
adverse event reports associated with the use of tobacco products from
interested parties such as health care providers, researchers,
consumers and other users of tobacco products. Information collected in
voluntary adverse event reports will contribute to CTP's ability to be
informed of, and assess the real consequences of, tobacco product use.
The need for this collection of information derives from our objective
to obtain current, timely, and policy-relevant information to carry out
our statutory functions. The FDA Commissioner is authorized to
undertake this collection as specified in section 1003(d)(2) of the
FD&C Act (21 U.S.C. 393(d)(2)).
CTP currently receives adverse event and product problem reports
primarily via paper MedWatch forms, approved under OMB control number
0910-0291. MedWatch forms, although recently updated with field labels
and descriptions to better clarify for reporters the range of
reportable products, including tobacco products, do not specifically
include questions relevant for the analysis of adverse events or
product problems related to tobacco products. The proposed voluntary
tobacco product adverse event and product problem rational
questionnaire will include these specific questions. The questionnaire
evolved with input from a National Institutes of Health team of human-
factors experts, from other regulatory Agencies, and with extensive
input from consumer advocacy groups and the general public. FDA is also
working with the FDA Internet team to follow the Department of Health
and Human Services Internet guidelines for Web design. FDA has and will
continue to reach out to professional organizations and community
interest groups to collect feedback during the user acceptance testing.
The rational questionnaire will provide the user with detailed
navigation instructions to include drop-down menus, lists of values,
controlled vocabularies, and mouse over help where possible. In
addition, CTP will issue guidance for the rational questionnaire.
Finally, we note that users who are unable to submit reports using the
electronic system will still be able to provide their information by
paper form (by mail or FAX) or telephone.
The proposed voluntary tobacco product adverse event and product
problem rational questionnaire requests the following information:
Introductory Information About the Submission
Whether the submission is a new report, or a followup or
amendment to a previously transmitted report.
Information About the Sender and the Affected Person
Unless the sender wishes to remain anonymous, the name of
and contact information for the person sending the report; and
Unless the affected person wishes to remain anonymous, the
name, contact
[[Page 3436]]
information, and demographic information for the person who experienced
the adverse event.
Details of Any Attachments
The type of attachment and a description of it.
Tobacco Product Details
Information about the product that is the subject of the
report, such as the brand name, product name, UPC, and a description of
the tobacco product or component;
Information about the product or component purchase date
and location; and
Information about the manufacturer of the product or
component.
Problem Summary
Information about the product problem or adverse event,
such as the date and duration of the problem or adverse event, a
description of the use of the product, a description of the product
problem or adverse event, and a description of the main symptoms or
health problems.
Information about the medical treatment received by the
affected person, such as whether the person was taken to an emergency
facility, a description of any medical testing or treatment performed,
and the results of any tests;
Information about any similar product problems or adverse
events previously had by the affected person; and
In the event of death, the date of death and the reported
cause of death.
Other Products Used
Information about the affected person's use of other
tobacco products, alcohol, prescription medications, over-the-counter
medications, vitamins, or dietary supplements.
The rational questionnaire will capture tobacco-specific adverse
event and product problem information from voluntary reporting entities
such as health care providers, researchers, consumers, and other users
of tobacco products. To carry out its responsibilities, FDA needs to be
informed when an adverse event, product problem, or error with use is
suspected or identified. When FDA receives tobacco-specific adverse
event and product problem information, it will use the information to
assess and evaluate the risk associated with the product, and then FDA
will take whatever action is necessary to reduce, mitigate, or
eliminate the public's exposure to the risk through regulatory and
public health interventions.
In the Federal Register of September 14, 2012 (77 FR 56847), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
II. Information Collection Burden Estimate
Description of respondents: The respondents to this collection of
information include all persons submitting mandatory or voluntary
adverse event reports electronically to FDA via the ESG or the SRP.
FDA estimates the burden of this collection of information as
follows:
Table 2--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average
Activity FDA Form No. Number of responses per Total annual burden per Total hours
respondents respondent responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Voluntary Adverse Event Report via the SRP (Other than 3800 1,513 1 1,513 0.6 908
RFR Reports)........................................... (36 minutes)
Mandatory Adverse Event Report via the SRP (Other than 3800 636 1 636 1 636
RFR Reports)...........................................
Mandatory Adverse Event Report via the ESG (Gateway-to- 3800 1,491,228 1 1,491,228 0.6 894,737
Gateway transmission).................................. (36 minutes)
Mandatory and Voluntary RFR Reports via the SRP......... 3800 1,413 1 1,413 0.6 848
(36 minutes)
-----------------------------------------------------------------------------------------------
Total............................................... .............. .............. .............. .............. .............. 897,129
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
The Agency's estimate of the number of respondents and the total
annual responses in table 2, Estimated Annual Reporting Burden, is
based primarily on mandatory and voluntary adverse event reports
electronically submitted to the Agency. The estimated total annual
responses are based on initial reports. Followup reports, if any, are
not counted as new reports. Based on its experience with adverse event
reporting, FDA estimates that it will take a respondent 0.6 hour to
submit a voluntary adverse event report via the SRP, 1 hour to submit a
mandatory adverse event report via the SRP, and 0.6 hour to submit a
mandatory adverse event report via the ESG (gateway-to-gateway
transmission). Both mandatory and voluntary RFR reports must be
submitted via the SRP. FDA estimates that it will take a respondent 0.6
hour to submit a RFR report, whether the submission is mandatory or
voluntary.
Voluntary adverse event reports submitted via the SRP (other than
RFR Reports) include reports associated with pet food (the Pet Food
Early Warning System) and the new tobacco product adverse event and
product problem reports. The Center for Veterinary Medicine (CVM)
received 845 pet food adverse event reports in 2010; 1,293 reports in
2011; and 471 reports in the first 4 months of 2012, and estimates that
for the full 12 months of 2012 it will receive 1,413 reports. Based on
this experience, CVM estimates that it will receive, on average, 1,413
pet food reports annually over the next 3 years. CTP estimates that it
will receive approximately 100 voluntary tobacco product adverse event
and product problem reports annually, after implementation of
electronic reporting. CTP received 27 reports in 2010, 30 reports in
2011, and 22 reports in the first half of 2012, and estimates that for
the full 12 months of 2012 it will receive over 40 reports. Based on
this experience and an expectation that reporting will increase once
electronic
[[Page 3437]]
reporting is launched, CTP estimates that it will receive, on average,
100 voluntary adverse event and product problem reports annually over
the next 3 years. Thus, FDA estimates that over the next 3 years it
will receive annually 1,513 voluntary adverse event reports submitted
via the SRP, with a burden of 907.8 hours, rounded to 908 hours, as
reported in table 2, row 1 (1,413 + 100 = 1,513).
Mandatory adverse event reports submitted via the SRP (other than
RFR Reports) include reports of adverse animal drug experiences and
product/manufacturing defects associated with approved NADAs and
ANADAs. CVM received 144 such adverse event reports in 2010, 537
reports in 2011, and 212 reports in the first four months of 2012, and
estimates that for the full 12 months of 2012 it will receive 636
reports. Based on this experience, CVM estimates that it will receive,
on average, 636 reports of adverse drug experiences and product/
manufacturing defects associated with approved NADAs and ANADAs
annually over the next 3 years. Thus, FDA estimates that over the next
3 years it will receive annually 636 mandatory adverse event reports
submitted via the SRP, with a burden of 636 hours, as reported in table
2, row 2.
Adverse event reports submitted via the ESG include reports of
adverse experiences related to drugs, biological products, and medical
devices, as well as, adverse animal drug experiences and product/
manufacturing defects associated with approved NADAs and ANADAs. FDA
received 586,229 such adverse event reports in 2010; 850,161 reports in
2011; and 497,076 reports in the first 4 months of 2012; and estimates
that for the full 12 months of 2012 it will receive 1,491,228 reports.
Based on this experience, FDA estimates that it will receive, on
average, 1,491,228 adverse event reports submitted via the ESG, with a
burden of 894,736.8 hours, rounded to 894,737 hours, as reported in
table 2, row 3.
FDA estimates that over the next 3 years it will receive annually
1,413 mandatory and voluntary RFR Reports submitted via the SRP, as
reported in table 2, row 4. The Center for Food Safety and Applied
Nutrition (CFSAN) received 845 such adverse event reports in 2010;
1,293 reports in 2011; and 471 reports in the first four months of
2012; and estimates that for the full 12 months of 2012 it will receive
1,413 reports. Based on this experience, CFSAN estimates that it will
receive, on average, 1,413 mandatory and voluntary RFR Reports
submitted via the SRP annually over the next 3 years, with a burden of
847.8 hours, rounded to 848 hours, as reported in table 2, row 4.
The burden hours required to complete paper FDA reporting forms
(Forms FDA 3500, 3500A, 1932, and 1932a) are reported under OMB control
numbers 0910-0284 and 0910-0291.
While FDA does not charge for the use of the ESG, FDA requires
respondents to obtain a public key infrastructure certificate in order
to set up the account. This can be obtained in-house or outsourced by
purchasing a public key certificate that is valid for 1 year to 3
years. The certificate typically costs from $20 to $30.
Dated: January 10, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-00761 Filed 1-15-13; 8:45 am]
BILLING CODE 4160-01-P